Saturday 31 October 2026 Export MRNA’s income statement to Excel — free account

Moderna, Inc.

MRNA Healthcare Biotechnology

Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024.

Revenue: +2.11%
EPS: +7.51%
Free cash flow: +38.9%
Total debt: +1,765.6%

Quarter to June 2026, against a year earlier

221.72 1.04 −0.47%

Follow MRNA

Alert me

Market cap: $88.9B
P/E: 0.0×
Fwd P/E: −26.1×
Dividend yield: —
F-score: 3/9
Altman Z: 2.46
Beneish M: −3.52
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Filings

Moderna, Inc. (MRNA) P/S ratio

Alert me on P/S ratio

As of 30 October 2026, Moderna, Inc. (MRNA) trades at a P/S ratio of 39.5×. Over the past ten years it has ranged from 0.0× (December 2018) to 543× (May 2020); the current reading is higher than 75% of that period. That is above the Biotechnology industry median of 10.5× and above the Healthcare sector median of 3.6×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/MRNA/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Moderna, Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/MRNA/metrics/ps-ratio">Moderna, Inc. (MRNA) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	5.9×	19.60%
FY2024	4.9×	(21.38%)
FY2023	6.3×	71.42%
FY2022	3.7×	(33.93%)
FY2021	5.5×	(88.82%)
FY2020	49.6×	(54.06%)
FY2019	108×	1,076.69%
FY2018	9.2×	—
FY2017	0.0×	—
FY2016	0.0×	—

Period	P/S ratio	Change
Jun 2026	12.5×	38.71%
Mar 2026	9.0×	52.83%
Dec 2025	5.9×	30.75%
Sep 2025	4.5×	29.77%
30 more quarters	Free account

Against its own ten years

Low 0.0× High 543×

Ten-year median 8.4×

Current reading's percentile 75

Company	P/S ratio
REGN Regeneron Pharmaceuticals, Inc. compare	6.1×
ONC BeOne Medicines Ltd. - Sponsored ADR compare	6.8×
GMAB Genmab A/S Sponsored ADR compare	8.5×
ARGX argenex SE compare	10.5×
VRTX Vertex Pharmaceuticals Incorporated compare	11.3×
RPRX Royalty Pharma PLC compare	11.8×
MRNA Moderna, Inc.	39.5×
RVMD Revolution Medicines, Inc. compare	1,505×
ROIV Roivant Sciences Ltd. compare	3,545×
Biotechnology industry median	10.5×
Healthcare sector median	3.6×
Market median	2.0×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Moderna, Inc. (MRNA) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on MRNA

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on MRNA

Stockrow Weekly